Company News

CDE accepted GMA204 IND registration and started on-site inspection

-

October 29, 2015, the IND registration of GMA204 was accepted by CDE, and an on-site inspection is about to start.

 

GMA204 is the first molecule of Gmax to move to IND filing. As the second generation of EGFR TKI for non-small cell lung cancer (NSCLC), GMA204 works better in EGFR wild type and T790 mutation tumor models compared with the first-generation EGFR TKI. Moreover, GMA204 could penetrate through blood brain barrier (BBB), which could target the brain metastasis of lung cancer.